Jaguar Health (NASDAQ: JAGX) was recently featured in a B2i release spotlighting the company’s focus on developing first-in-class, plant-based treatments for gastrointestinal (“GI”) disease. The release noted that JAGX and its family company Napo Pharmaceuticals are specifically looking at treating overactive bowel, which causes debilitating symptoms such as chronic debilitating diarrhea, GI urgency and GI incontinence in both humans and animals. The new initiative with B2i is part of a strategic campaign designed to increase investor engagement and interest.
“The most critical near-term catalysts are the expected availability in late Oct. 2023 of top-line results of Napo’s phase 3 clinical trial to expand crofelemer into the preventative treatment of chemotherapy-induced overactive bowel (‘CIOB’) in adults with cancer on targeted therapy, and the generation of proof-of-concept data by the end of 2023 and in 2024 to expand crofelemer into two rare disease indications: short bowel syndrome (‘SBS’) and microvillus inclusion disease (‘MVID’) with intestinal failure,” stated the B2i Digital release. “Jaguar Health offers several key strengths for investors to consider: Jaguar Health is developing multiple formulations of its key product, crofelemer, to treat different gastrointestinal diseases; canalevia-CA1 is the first and only product indicated for CID in dogs to receive any type of approval from the FDA; beyond its core focus, Jaguar Health has invested in an intriguing new venture targeting mental health disorders through natural plant-based prescription drugs.”
To view the full press release, visit https://ibn.fm/8wnMP
About Jaguar Health Inc. and Napo
Jaguar Health along with its family company, Napo, is a commercial-stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency and bowel incontinence. Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals’ crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal phase 3 clinical trial for preventive treatment of CIOB in adults with cancer on targeted therapy. Napo Therapeutics is an Italian corporation established in Milan, Italy, in 2021 focused on expanding crofelemer access in Europe, specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp., is focused on developing novel prescription medicines derived from plants for mental health indications. For additional information about this company, visit www.Jaguar.Health.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
